Overview of Беринерт

Quick Facts

Property	Description
Active Ingredient	C1-esterase Inhibitor (human) (C1-INH)
Form	Lyophilized powder for solution for injection
Pharmacological Class	Complement Inhibitor / Serine Protease Inhibitor
Common Use	Acute attacks related to Hereditary Angioedema (HAE)
Origin	Plasma-derived (Purified from human blood)

What Type of Medicine is Беринерт?

Беринерт (Berinert) is a specialized, prescription-only biological medicine that functions as a protein replacement therapy. Its active ingredient is the C1-esterase Inhibitor (human) (C1-INH), which belongs to the pharmacological class of Complement Inhibitors and is clinically recognized as a Serine Protease Inhibitor (Serpin). This classification signifies a medicine that directly regulates specific immune and inflammation pathways in the blood.

The fundamental purpose of Беринерт is to supply a critical protein that is either insufficient or dysfunctional in individuals with Hereditary Angioedema (HAE). This targeted mechanism is supported by pharmacological studies and provides a highly specific form of treatment distinct from general anti-inflammatory drugs.

Is Беринерт a Natural or Synthetic Product?

Беринерт is classified as a plasma-derived product, a key feature distinguishing it from synthetically manufactured therapies. Its active ingredient is purified and concentrated from large pools of donated human blood plasma. This extensive process ensures the C1-esterase Inhibitor is structurally identical to the protein naturally produced in the body. The medicine is supplied as a single-dose, lyophilized powder concentrate that is prepared for intravenous (IV) injection.

What is the General Purpose of Беринерт?

The general purpose of Беринерт is to quickly halt acute swelling attacks by correcting the protein imbalance in the blood. The supplemental C1-INH rapidly acts to inhibit the chemical reaction that leads to the excessive release of the potent inflammatory chemical bradykinin. By restoring this natural control mechanism, the medicine is designed to provide rapid relief and prevent the progression of severe swelling episodes for adults and pediatric patients alike.

What side effects are possible with Беринерт?

Possible Side Effects and Safety Information

Berinert is a C1 Esterase Inhibitor (Human) concentrate used to treat hereditary angioedema (HAE) attacks. The safety profile is characterized by risks related to its plasma-derived nature, the potential for serious allergic reactions, and the risk of thromboembolic events.

Key Safety Considerations

Serious Thromboembolic Events (TE): Serious arterial and venous thromboembolic events have been reported following the administration of C1 esterase inhibitor products. Individuals with pre-existing risk factors for thrombosis (such as indwelling catheters, history of prior thrombosis, immobility, or use of oral contraceptives) may be at an increased risk and require close monitoring during and after treatment.

Hypersensitivity Reactions: Life-threatening systemic hypersensitivity reactions, including anaphylaxis, are possible. The product is contraindicated in patients with a known history of severe systemic reactions to C1 esterase inhibitor preparations. Appropriate medical support, including epinephrine, should be immediately available for the treatment of acute severe reactions.

Infectious Agent Risk: Because Berinert is made from human plasma, the risk of transmitting infectious agents, such as viruses and theoretically the agents of Creutzfeldt-Jakob Disease (CJD), cannot be completely eliminated. Manufacturing processes include steps designed to reduce this risk.

Adverse Reactions

The most common adverse reaction reported in controlled clinical trials was dysgeusia (a bad taste in the mouth). Other reactions observed have included headache, nausea, abdominal pain, vomiting, and diarrhea. The most serious adverse reaction reported in clinical studies was an increased severity of pain associated with HAE.

System-Organ Class Involved	Key Reactions Reported
Immune System	Hypersensitivity, Anaphylaxis
Vascular	Serious Thromboembolic Events
Nervous System	Headache, Dysgeusia
Gastrointestinal	Nausea, Abdominal Pain, Vomiting

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation states that no case of overdose has been formally reported for C1-esterase Inhibitor (human). Therefore, specific clinical manifestations of overdose are not described.

Documented High-Dose Risks

Regulatory warnings define the primary risk associated with elevated exposure as the potential for serious arterial and venous thromboembolic (TE) events. These events have been reported when C1-esterase Inhibitor products are used for unapproved indications at higher than recommended doses.

Official Emergency Actions Required

Immediate medical help is required in the following documented scenarios, based strictly on prescribing information:

Laryngeal Attacks: Patients must immediately seek medical attention following self-administration for a laryngeal hereditary angioedema (HAE) attack.
Administration Issues: Urgent help must be sought if the progression of the HAE attack prevents the ability to properly prepare or administer the dose.
Severe Hypersensitivity: If severe hypersensitivity or anaphylaxis is suspected, administration must be immediately discontinued. Regulators mandate that epinephrine should be immediately available for treating acute, severe allergic reactions.

Due to the medicine being a replacement protein, no specific pharmacological antidote is documented in the official labeling; treatment relies on mandated supportive measures for the manifested symptoms.

Therapeutic Uses of Беринерт

What Беринерт Treats: Main Uses and Benefits

The primary use of Беринерт is relevant for easing symptoms related to sudden and debilitating swelling episodes, known as acute attacks, in individuals diagnosed with Hereditary Angioedema (HAE). This treatment is applied in scenarios where short-term symptomatic assistance is needed during phases that involve acute or unstable symptom patterns. It supports the management of symptom escalation during episodic symptomatic manifestations of the disease and provides supportive relief when symptoms interfere with daily functioning.

The medicine's relevance spans acute abdominal, facial, and laryngeal hereditary angioedema attacks in adult and pediatric patients.

Intervention for Critical Internal and Airway Symptoms

Беринерт is commonly used for managing the most concerning HAE symptoms, including laryngeal swelling that creates noticeable physiological strain and severe abdominal attacks marked by intense pain. By providing temporary assistance in symptom stabilization, it offers symptomatic relief that helps patients cope more steadily with these difficult, heightened episodes and may assist with support for functional stability in the airway.

Quick Fact: Relief for Acute HAE Attacks
Primary Use Focus	Acute swelling episodes
Key Symptom Clusters	Laryngeal, abdominal, or facial edema
Patient Benefit	Contributes to support for functional stability
Context of Use	Applied in acute or unstable symptom patterns

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Беринерт

This section details the official population eligibility and non-eligibility rules for Беринерт (C1-esterase Inhibitor [Human]), based strictly on regulatory documents.

Eligibility scope	Detail (Regulatory Wording)
Populations for whom use is allowed	Adult and Pediatric patients for the treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks.
Populations for whom use is contraindicated	Individuals with a history of life-threatening systemic hypersensitivity reactions, including anaphylaxis, to C1-esterase inhibitor preparations.
Age-related eligibility rules	Approved for adult and pediatric patients. The safety and efficacy for prophylactic therapy (prevention) have not been established in any age group.
Pregnancy and lactation eligibility status	Use is advised only if clearly needed during pregnancy and lactation due to limited data.
Eligibility-related restrictions	Patients with known risk factors for thromboembolic (TE) events require the weighing of benefits against risks and must be closely monitored during and after administration. Risk factors include prior history of thrombosis, use of oral contraceptives/certain androgens, and indwelling venous access devices.

Connection to the overall eligibility profile:

Regulatory documents define who can and cannot use Беринерт by establishing a single absolute contraindication related to prior hypersensitivity. Eligibility is confirmed across all age groups (adult and pediatric) but is strictly limited to the acute treatment of HAE attacks. Special consideration and mandatory monitoring are required for patients with specified thromboembolic risk factors, reflecting a crucial conditional-use constraint defined by the official label.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents emphasize specific procedural and co-administration constraints for this product, which is a concentrate of C1 esterase inhibitor (human).

Documented Interaction Constraints

Constraint Type	Interacting Product/Category	Regulatory Statement
Procedural (Admixture)	All other medicinal products or solutions	Do not mix this product with other medicinal products or solutions. Administer by a separate infusion line.
Risk Factor Enhancement	Oral Contraceptives / Certain Androgens	Use of these products is identified as a potential risk factor for serious arterial and venous thromboembolic events.

Clinical and Procedural Requirements

No formal pharmacokinetic drug-drug interaction studies between this product and other medicines have been performed or are generally documented in regulatory labeling. The documented profile focuses on two distinct areas:

Physical/Chemical Incompatibility: The product must be administered only after reconstitution with the specified diluent and must never be co-administered or mixed with any other intravenous medicine or solution. This is a mandatory procedural constraint to ensure product integrity and proper administration.
Thrombosis Risk Factors: Co-administration with certain medication classes, specifically oral contraceptives and certain androgens, is officially noted in warnings because these products may increase the underlying risk of thromboembolic events, which are a documented safety concern for C1 Esterase Inhibitor (Human) products. Patients with known risk factors, including the use of these medicines, require monitoring during and after product administration, as specified in official labeling.

These constraints establish a regulatory structure that primarily mandates safe handling (non-admixture) and requires heightened monitoring when the product is used concurrently with specific hormones that raise the risk of blood clots.

Mechanism of Action

Inhibition of Key Serine Proteases

The drug's core action is the rapid and irreversible inactivation of critical circulating enzymes, notably Plasma Kallikrein and Coagulation Factor XIIa. As a replacement protein, the C1-esterase Inhibitor (C1-INH) forms a stable, covalent complex with these active proteases, effectively neutralizing their ability to drive downstream cascades and contributing to the regulation of downstream cascades.

Modulation of the Contact System

By neutralizing Plasma Kallikrein, the mechanism prevents the uncontrolled cleavage of kininogen, which is the necessary step for generating excessive amounts of the vasoactive peptide, bradykinin. This targeted suppression of bradykinin generation acts as the direct physiological countermeasure against the pathological activation patterns in the Kallikrein-Kinin System.

Stabilization of Vascular Integrity

The systemic consequence of reduced bradykinin levels is the rapid normalization of vascular permeability, which is the physiological process governing fluid movement across blood vessel walls. This regulatory effect stabilizes the endothelial barrier function, which results in the physiological reversal of excessive fluid extravasation.

Dosage and Administration Information

How Беринерт is Used

Беринерт (C1-esterase Inhibitor, human) is administered exclusively as a solution for intravenous (IV) injection. The medicine is supplied as a lyophilized powder and must be reconstituted with the supplied sterile water prior to use. The administration protocol is defined by standardized clinical protocols, focusing on use during acute symptomatic events.

Dosing and Administration Protocol

The standard quantity administered is calculated based on the recipient's weight. The official dose for treating an acute Hereditary Angioedema (HAE) attack in adults and pediatric patients is 20 International Units (IU) per kilogram of body weight. Because this medicine is for acute intervention, it is used on an as-needed (on-demand) basis and is not a continuous, daily prophylactic therapy.

In scenarios where HAE symptoms remain uncontrolled, a second dose may be administered after an interval of at least one hour has passed from the initial injection.

Specific Use Constraints

The entire administration process is governed by specific procedural requirements. The reconstituted solution must be administered slowly by intravenous injection, typically at a rate of approximately 4 mL per minute. The product is not intended to be mixed with other medicinal products or intravenous fluids and must be delivered through a separate infusion line. For certain medical or dental procedures, a pre-procedure prophylactic dose of 1000 IU for adults or 15 to 30 IU/kg for children may be administered less than six hours prior to the procedure.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Беринерт

This section summarizes the published research available for C1-esterase Inhibitor (human), detailing the types of studies conducted, the populations included, and the outcomes that were measured in research. This information describes group patterns observed in research settings.

Evidence for Use in Acute HAE Attacks

Research exploring the use of this medicine for sudden, acute swelling episodes has primarily relied on randomized, double-blind, placebo-controlled clinical trials (RCTs). These are a type of study used in research exploring how symptoms change over time in abdominal and facial swelling attacks. Researchers were primarily interested in the time to the onset of initial symptom relief and the time required for complete symptom resolution in study participants.

For laryngeal (throat) swelling attacks, which are conditions associated with acute or disruptive episodes, studies could not ethically use a placebo comparator. Therefore, research for laryngeal attacks was conducted in open-label study designs, where all participants were closely monitored. These studies observed how symptoms evolved in the observed populations. Research highlights changes measured during the study period; studies reported measurements of the time to relief in the group receiving the medicine compared to the placebo group. The evidence provides insight into symptom patterns during acute attacks.

Structure of Primary Clinical Trials

The main clinical trials included both adult and pediatric patients with the condition. The studies monitored outcomes related to physical discomfort and outcomes describing episodic or acute changes. The primary goal of these studies was to monitor physiological strain or stress and to use precise measurements to assess outcomes related to symptom intensity. The findings describe group patterns and reflect the specific conditions under which they were conducted.

Evidence Structures for Prophylactic (Preventative) Use

Research has also explored the use of C1-esterase Inhibitor for preventing attacks, although the available evidence is different in structure compared to the acute treatment studies. This research includes controlled crossover trials and large, long-term patient registry studies. The primary outcomes research examined were the frequency or incidence rate of HAE attacks per time period, which reflects outcomes capturing phases of heightened symptom activity. Findings varied across studies, and data show patterns related to differences in attack frequency during the study period compared to a period without the medicine or placebo.

Frequently Asked Questions (FAQ)

Common questions about Беринерт (FAQ)

Q: How quickly does Berinert start to work during an acute attack?

Studies and official information indicate that the onset of relief varies by the type of swelling attack. Clinical trials reported that the median time to initial symptom relief for laryngeal attacks was 15 minutes. For abdominal and facial swelling attacks, the median time to initial relief observed in trials was 48 minutes.

Q: How long does the effect last after Berinert is administered?

The duration of the drug's presence in the body is described by its half-life, which is the time required for the concentration in the blood to decrease by half. Official pharmacokinetic studies indicate that the average half-life in adults ranges from 7.4 to 22.8 hours.

Q: Is Berinert effective for all types of HAE attacks (e.g., abdominal, facial, laryngeal)?

Regulatory documents state that the medicine is indicated for treating acute episodes of Hereditary Angioedema (HAE) that affect the abdomen, face, or throat (larynx). This means the therapy is officially used across all three major sites of acute swelling.

Q: What signs of an allergic reaction warrant immediate medical evaluation after using Berinert?

The official patient information describes several signs of a serious allergic reaction that warrant immediate medical evaluation. These are official signs that can include hives, chest tightness, wheezing, difficulty breathing, swelling of the face, lips, or throat, and a rapid heartbeat.

Q: Are there known interactions between Berinert and other medicines that increase the risk of thrombosis?

While no formal drug-drug interaction studies have been documented, official warnings highlight that oral contraceptives and certain androgens may increase the risk of blood clots. Official guidance emphasizes the importance of discussing all current medications with a healthcare provider, especially those that could influence the risk of blood clots.

Q: Does Berinert affect the ability to drive or operate machinery?

Official product information states that the medicine has no known effect on the ability to drive or use machines. However, patients should be aware that some reported side effects, such as headache or dizziness, may temporarily impact their ability to perform such tasks.

Q: Is special training required for self-administration of Berinert?

According to regulatory patient counseling information, if the medicine is to be self-administered at home, appropriate training is required. This training is typically provided and supervised by a healthcare professional.

Q: Is Berinert always administered intravenously?

The medicine is available in two distinct forms based on its intended use. One form is for intravenous (IV) injection, which is typically used for treating acute attacks. The other form is designed for subcutaneous (SC) injection, which is often used for the prevention (prophylaxis) of attacks.

Q: What should be done if the swelling attack does not subside after using Berinert?

Official patient guidelines recommend contacting a healthcare provider immediately if swelling is not controlled or does not subside after administration. Depending on the clinical situation, the doctor may then decide whether a second dose is appropriate.

Q: What types of HAE attacks are considered most life-threatening and require immediate treatment?

According to regulatory and clinical guidelines, Hereditary Angioedema attacks that affect the throat (laryngeal attacks) are considered potentially life-threatening. Regulatory and clinical guidelines indicate that this type of attack warrants immediate medical treatment.

Q: Is it necessary to take Berinert when traveling?

Official storage requirements provide the necessary guidelines for travel logistics. The unopened product should be stored in its original carton to protect it from light, and it can be kept at temperatures up to 30 °C (86 °F) until reconstitution.

Q: What should be done if Berinert looks cloudy or contains particles after reconstitution?

The official reconstitution instructions mandate checking the appearance of the solution. The reconstituted medicine should be clear and colorless. If the solution appears cloudy, discolored, or contains particles, official instructions indicate that it should not be used, and a healthcare professional or pharmacist should be consulted for a replacement.

Q: What is the role of C1-esterase inhibitor (C1-INH) in the human body?

The C1-esterase Inhibitor (C1-INH) is a natural protein that helps regulate the body's immune and inflammation pathways. It works by neutralizing key enzymes, such as plasma kallikrein, which would otherwise lead to the overproduction of the inflammatory substance bradykinin. This action helps restore the body’s natural control mechanism.

Q: Why is it important to seek immediate medical attention after administering Berinert for a laryngeal attack?

Patient counseling materials state that seeking immediate medical attention after self-administering the medicine for a laryngeal attack is required. This is due to the potential severity and life-threatening nature of swelling in the throat.

Q: Can Berinert be used if I have a history of cardiovascular diseases?

Regulatory warnings advise caution for patients with a history of cardiovascular diseases, including heart problems, stroke, or blood clots. Regulatory warnings indicate that patients with such conditions should ensure their full medical history is discussed with their healthcare provider and may require careful monitoring during and after administration.

Q: Is a special type of syringe required for Berinert administration?

In the case of subcutaneous (SC) administration, official instructions mention the use of specific components for preparation and injection. Product monographs may specify the use of silicone-free syringes to maintain the stability and integrity of the medicine.

Q: Can Berinert be used to treat swelling caused by reasons other than HAE?

Official indication statements strictly limit the use of the medicine. It is indicated only for the treatment of acute Hereditary Angioedema (HAE) attacks and is not approved or intended for treating swelling caused by other conditions, such as allergic reactions or drug-induced angioedema.

Q: What part of the body is Berinert usually injected into for self-administration?

For self-administration via subcutaneous (SC) injection, the official instructions recommend the abdominal area as the injection site. Official instructions recommend rotating the injection sites for subsequent doses.

Q: Why is it important to record the date and batch number of Berinert after administration?

Regulatory traceability requirements for biological products mandate that the name and batch number of the administered medicine be clearly recorded. This procedure supports pharmacovigilance (monitoring drug safety) and ensures proper product tracking.

How should Беринерт be stored and disposed of?

How to Store and Dispose of Berinert

The storage and disposal of Berinert must strictly follow regulatory labeling to ensure product integrity and proper pharmaceutical waste handling.

Storage Requirements

Product State	Storage Conditions	Stability/Constraints
Unopened Vial	Store in the original carton between 2 °C and 30 °C (36 °F and 86 °F)	Do not freeze. Protect from light. Keep out of the reach of children.
Reconstituted Solution	Store in the vial at room temperature (IV) or below 30 °C (SC)	Must be used promptly. The intravenous solution must be used within 8 hours. The subcutaneous solution must be used within 6 hours.

Disposal Instructions

Berinert is a single-use product; any unused portion of the reconstituted solution must be discarded. Used needles, syringes, and vials must be immediately disposed of in a designated sharps container. Unused medicine and waste materials must be disposed of according to local regulatory requirements, and should not be placed in household waste or wastewater.

Беринерт